A relatively young medical field, the US fertility market is a rapidly evolving landscape from a scientific, technological and a business standpoint. Recent advances in treatment have helped improve success rates, reduce rates of multiple gestations, and decrease time to pregnancy.
While disease awareness and utilization of Assisted Reproductive Technology (ART) services has increased, drug development in infertility has stagnated. Shortages across multiple drug classes have been reported as recently as 2018.
Competition spurs innovation.
New market entries, aimed at increasing competition and improving the patient experience, will benefit both clinicians and patients in this rapidly growing market.
In the US, approximately 1 in 8 (12%) of married couples has trouble getting pregnant or sustaining a pregnancy
The number of ART cycles (or IVF) in the U.S. has increased 50% from 2012 to 2016
It is estimated that only 44% of women with infertility have sought medical treatment
Patients cite cost and burden of treatment as the primary reasons they do not seek or continue treatment